H Bfrin

 

 

  

Hypothesis:

BRAINco harom schizopnvolved in n

The modu

as carried ophrenic patneurotransm

ulation of ne

Refne

BRAINco

New

Exocy

Advant

• A

o

• A

p

v

• M

out extensivtients that h

mitter releas

eurotransm

ATPDocking

filling withurotransmitter

o target

Sy

 

treatmytosis mod

tages:

A novel me

on neurotr

A novel the

postmortem

validated i

Molecules

ve genomic had commi

se have been

mitter relea

Ca

Neurotrreceptor

Priming

Ca2+

s

ynaptic vesicles

LICE

ment for dulators f

echanism

ransmissio

erapeutic

m brain fr

in unique c

modulatin

and proteoitted suicidn found in th

ase may pla

a2+

ansmitterr

Fusion

+

H+

s

ENSIN

Schizofor the tre

of action:

on.

target whi

rom schizo

cellular an

ng the syst

omic analysde. Increaseheir prefron

ay a crucial

Ca2+

Early en

E

NEUROT

NG OPP

phreniaeatment of

the exocyt

ich has bee

phrenic pa

nd transge

tem have a

is of humand expressio

ntal cortex.

l role in the

Syn

Presy

Posts

ndosome

Endocytosis

H+

TRANSMISSIO

PORTU

a of Schizop

tosis impli

en found al

atients, and

enic anima

already be

n postmorteon levels o

e future of

naptic Cleft

ynaptic membra

synapticmembra

ON

UNITY

phrenia

icated dire

ltered in h

d has been

al models.

een identif

em brain tisf a key pro

antipsycho

ne

ane

Y

ectly

human

fied.

ssues otein

otics.

BAC

BRAin viveffic

 TOO

A relfrom Thengene

Cel

Severeleabioel

Sevetissu

Targeident

 

 

  

CKGROUN

AINco aims tvo models anacy in the tra

Exocytosisspecific: dBRAINco is based on

OL GENER

levant incream Schizophren

n, BRAINco erated for val

ll based assa

eral cellular base with diffelectrical assa

The effect ousing severaresults fromThe radioactvalidated forA fluorescenbeing adapte

eral assays ine specificity

et tification

ND

o validate thnd find moleansgenic anim

s takes placedifferent isofo

expects to ann neuronal c

RATION A

ase of the targnia subject, m

has validatelidation will b

ay:

based assays erent read-ouays:

f target on exal cellular ba

m the radioacttive assay har screening nt assay baseed to HCS.

n cell lines de. 

In smo

Assay development

Animal model

he implicationcules with a mal over exp

in almost evforms are expnticipate mo

cellular mod

AND TARG

get has beenmodulated by

d the target abe used to de

have been suts: radioact

xocytosis haased assays, ative assay in as been adapt

ed on a mole

erived from d

Devel

Target validation 

silicoodeling

 

n of the targegood preclin

pressing the t

very tissue hopressed depenolecules specdels, 2) Targe

Figure 1

GET VALI

n found in humby antipsycho

at animal andevelop the pr

et up to meaivity, fluores

as been validaas an examplFig.2. ted to HTS a

cular probe i

different peri

lopmen

Virtual screening

Primary assay

et in the etiopnical profile target of inte

owever the pnding on theificity issues

et focused ap

 1: Workflow of th

DATION

man postmootic treatmen

d cellular levroject.

asure neurotrascent probes

ated le

and

is

ipheral tissue

nt Stage

Screening campaing

In‐vitro testing 

Mole

B

pathogenia othat affect ne

erest.

proteins invoe cell type. s combining pproach done

he project

rtem brain nt (Fig.1).

vels, the tools

ansmitter and other

es have been

e: Cand

Hit toLead

ecule testing

Biomarker dis

Figure 2. Neuroand right: when

of the diseaseeurotransmit

olved in this m

two strategiee with specifi

s

n set up in ord

idate Id

Figure 1. tissue.

  Lead Opt.&

scovery

otransmitters relean target is knocke

e using in vittter release an

machinery a

es: 1) Cell bafic isoforms f

der to evalua

dentific

Target expression

Candipreclidevel

ase, left: when tad down.

tro as well asnd present

are tissue

ased approacfrom the bra

ate molecule

ation

n in brain post mo

idate for inicallopment

rget is overexpre

s

ch ain.

s

ortem

ssed

Tra

An anBehavschizo

We befo

CAN

Cel

Sever

Tar

A viridenti

Fig(tre

 

 

                                                    

ansgenic (TG

nimal modelvioral, morpophrenia like

Behavio

Increase iactivity (o

Social int Deficit in

(prepulse Deficit in

(new obje

are aiming aore the end o

NDIDATE F

lular based

ral chemicalA screeningidentified rA second shas been ouA third scre

rget focused

rtual screenintified in the t

A preliminavalidate boA virtual scperformed.protein inte

gure 3. Deficit in eated with antipsy

G) animal m

l over-expreshological, bie phenotype.

oral

in locomotioopen field). teraction defen sensoring g

inhibition) Fn working meect recognitio

at in vivo Proof the year.

FINDING

approach:

l starting poig with the Prrepresent oracreening witutlined. eening is bei

d approach:

ng has been ptarget by in sary virtual scth sites. creening with The molecu

eraction assay

PPI in TG mice ychotic) 

model:

ssing the targiochemical a.

n

fects. ating Fig.3. emory on).

oof of Conce

ints have beerestwick librally availableth a diverse l

ing planned w

performed agsilico modelicreening has

h millions ofules obtainedy adapted to

Devel

rget of intereand molecula

ept of the can

en identifiedary (1120 FD drugs. library (9652

with a differe

gainst two dring. been perform

f compoundsd will be teste

HTS (the H

lopmen

Figure 4. Chanvolume betwee

Morph

Brain vo Reductio

tracks. Increase

(Fig.4).

st has been gar characteriz

ndidates in ou

d so far. DA approval

2 compounds

ent methodo

ruggable site

med in order

s is now beined in a proteiTRF assay F

nt Stage

nges in brain and en WT and transg

hological alt

olume decreaon in white m

e in ventricle

generated. zations have

ur animal mo

l compounds

s) has been d

logy and a la

es

r to

ng in-

Fig.6).

e: Cand

Fventricles genic

teration

ase. matter

volume

Figurconce

shown that t

odel and oth

) has been pe

done and a sp

arger and mo

idate Id

Figure 5. LTP TG

Func

Reduc Altera

system Abnor

oscilla

e 6. HTRF assay entrations and dif

transgenic m

er classical a

erformed and

pecific chemi

ore diverse lib

dentific

G vs. Control (C5

ctional

ction in long ation of neuroms. rmality in baatory activity

Target/ Target pfferent fluorescen

mice present a

animal mode

d the hits

ical family

brary.

ation

57 & CBA/C57)

term potentiotransmitter

sal cortical y (Fig.5).

partner (different t TAGs)

a

els

iation.

Su

ScsHa Btcrc BNdrfit Ioedp

 

 

 ummarize

Schizophrencost reachesymptoms, However, alaction

BRAINco hissues from

certain proteresearch grocomplex dis

BRAINco hNowadays tdeveloped drelease of nefor one part,ts main part

In addition, others diseaencephalopadifferent tispatient strati

nia is currened €35 bill

together wlmost none

has carried m schizophreeins involveoups have sorder.

has built uthe target hdifferent ceeurotransmi, the mechatner involve

the expressases. At genathy. BRAINsues, includification.

ntly estimatlion. Curre

with their se of the pre

out extensenic patiented in exocytfurther sup

up a drug as been val

ellular and itters. BRA

anism of exoed in this m

sion of the netic level, mNco will asding the an

BRAINcEdificio 50jmasse@

ted to affectnt antipsycide effects,

esent drugs

sive genomits that had ctosis have b

pported thes

discovery lidated at hbiochemica

AINco set upocytosis and

mechanism.

target has amutations inssess the bi

nimal mode

co Biopharma4. Parque tecnológi

@brainco.es |

t around 1.chotics lack, has stressunder deve

ic and protcommitted sbeen found ise findings

program buman, animal assays up two approd for a seco

already beenn the target iochemical

el, as well a

a S.Lico de Vizcaya | 48 www.brainco

1% of the Uk of efficased the neelopment ar

teomic analsuicide. Altin the prefro, involving

based on emal and cellsed for fin

oaches in orond part, the

n found altehave also band functio

as patients

8160 Derio (Bilbao).o.es

US populatiacy particued for morre based on

lyses of huterations in ontal cortex the exocy

exocytosis lular levels.

nding molecrder to find e interaction

ered in Schbeen identifonal alteratiin order to

. Vizcaya. Spain | T

ion and its tularly againre effectiven a new me

uman postmthe express

x of these paytosis mach

and neurot. The compcules that mmolecules

n between t

hizophrenia fied in infanion of the e

o define the

elf: +34 94 406452

total medicnst cognitive treatmentechanisms o

mortem braision levels oatients. Othe

hinery in th

transmissionpany has alsmodulate ththat regulahe target an

as well as intile epileptexocytosis ie strategy fo

5 | Fax: +34 94 40

al ve ts. of

in of er

his

n. so he te

nd

in ic in or

06 4526